Home/Pipeline/Sarizotan

Sarizotan

Rett Syndrome

Phase IIIDiscontinued

Key Facts

Indication

Rett Syndrome

Phase

Phase III

Status

Discontinued

Company

Newron Pharmaceuticals

About Newron Pharmaceuticals

Newron Pharmaceuticals is a development-stage biopharma focused on novel therapies for neurological diseases. Its primary achievement is the global approval and commercialization of Xadago® for Parkinson's disease, providing a revenue foundation. The company's strategy centers on advancing a pipeline of innovative small molecules for rare CNS disorders, leveraging strategic partnerships to maximize reach while retaining key rights. With a lean operational model, Newron aims to address significant unmet medical needs in neuroscience.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Rett Syndrome Drugs

Drug	Company	Phase	Status
NTI164	Neurotech International	Phase 2	Active
RTT1	Grann Pharmaceuticals	Pre-clinical	Active
NEX-1 / NEX-2	Nexien BioPharma	Pre-clinical / Phase 1	Active
KIT-13	NeuroCores	Pre-clinical	Active
DPM-1003	DepYmed	Phase 1	Active
ExoEdit® for Rett Syndrome	Evox Therapeutics	Pre-clinical	Active
RVL-001 (vorinostat)	Unravel Biosciences	Clinical Trial Initiated	Active
Rett Syndrome Program	Herophilus	Discovery	Active
Glutamate Modulator for Rett Syndrome	Numedicus	Licensed/Orphan Designation	Active
TTI-0102	Thiogenesis Therapeutics	Phase 1	Planned
DAYBUE® (trofinetide)	Neuren Pharmaceuticals	Approved	Commercial
TSHA-102	Taysha Gene Therapies	Phase 1/2	Active (Pivotal-Enabling)